We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Heart Metabolics launched an open-label Phase IIb study of perhexiline in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure with preserved left ventricular function. Read More
The UK’s price watchdog has recommended reimbursement for Bayer’s prostate cancer drug Xofigo for an expanded indication, provided that the company delivers discounted prices as promised. Read More
Merck is suspending development of its osteoporosis candidate after an analysis of its Phase III fracture outcomes study demonstrated that the therapy increases the risk of strokes. Read More
A Phase III study of Tecentriq immunotherapy met its primary endpoints by showing improvements in overall survival, regardless of PD-L1 status, when compared with docetaxel chemotherapy in locally advanced or metastatic non-small cell lung cancer. Read More
FDA granted accelerated approval to Amgen’s Blincyto (blinatumomab) for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More
Amgen will move omecamtiv mecarbil, for the treatment of chronic heart failure, into Phase III development in collaboration with Cytokinetics. Read More
Presidential hopeful Hillary Clinton has unveiled a plan to rein in exorbitant drug costs for lifesaving treatments that would penalize drugmakers for price-gouging. Read More